UZH-Logo

Maintenance Infos

Therapies for childhood psoriasis


Trueb, R M (2009). Therapies for childhood psoriasis. Current Problems in Dermatology, 38:137-159.

Abstract

With a prevalence of 2% of the general population of Europe and North America, psoriasis represents one of the most common and significant dermatologic disorders. While it has been claimed that psoriasis is uncommon in children, in fact 27% of cases manifest before the age of 16 years; moreover, psoriasis represents 4.1% of all dermatoses seen in children under the age of 16 years. Both recognition and treatment of psoriasis in children represent unique challenges. Early diagnosis and appropriate management are particularly important in children to lessen long-term disease-related psychosocial problems and comorbidities. Psoriasis in childhood is a disease of many forms, which may change over time. It may be difficult to recognize, since the frequencies of some types of patterns of psoriasis differ between adults and children, and some clinical features are distinctive to the pediatric age group. Management involves education of the child and parents concerning the nature of the disease and the effects of treatment. Environmental triggers should be sought and eliminated, particularly infection, trauma, and stress. The treatment options available are basically the same as for adults, but special care should be taken in order not to endanger the development or the future health of the child. In children, treatment modalities are limited because of safety concerns and/or poor compliance associated with messy and time-consuming therapies. Randomized controlled clinical trials involving children under the age of 12 years suffering from psoriasis have been reported only for 2 topical treatments, namely, calcipotriol and corticosteroids. Phototherapy and systemic therapy with methotrexate, acitretin and cyclosporin have limited use because of lower tolerability in children and cumulative toxicities. For this reason, treatments of psoriasis with the newer biologic agents, particularly the soluble tumor necrosis factor receptor fusion protein etanercept, are emerging. Finally, it is important to acknowledge that topical and systemic treatments are only part of a 'total care' package combining treatment, disease-specific education, and psychological support to cope with a possible lifelong skin condition.

With a prevalence of 2% of the general population of Europe and North America, psoriasis represents one of the most common and significant dermatologic disorders. While it has been claimed that psoriasis is uncommon in children, in fact 27% of cases manifest before the age of 16 years; moreover, psoriasis represents 4.1% of all dermatoses seen in children under the age of 16 years. Both recognition and treatment of psoriasis in children represent unique challenges. Early diagnosis and appropriate management are particularly important in children to lessen long-term disease-related psychosocial problems and comorbidities. Psoriasis in childhood is a disease of many forms, which may change over time. It may be difficult to recognize, since the frequencies of some types of patterns of psoriasis differ between adults and children, and some clinical features are distinctive to the pediatric age group. Management involves education of the child and parents concerning the nature of the disease and the effects of treatment. Environmental triggers should be sought and eliminated, particularly infection, trauma, and stress. The treatment options available are basically the same as for adults, but special care should be taken in order not to endanger the development or the future health of the child. In children, treatment modalities are limited because of safety concerns and/or poor compliance associated with messy and time-consuming therapies. Randomized controlled clinical trials involving children under the age of 12 years suffering from psoriasis have been reported only for 2 topical treatments, namely, calcipotriol and corticosteroids. Phototherapy and systemic therapy with methotrexate, acitretin and cyclosporin have limited use because of lower tolerability in children and cumulative toxicities. For this reason, treatments of psoriasis with the newer biologic agents, particularly the soluble tumor necrosis factor receptor fusion protein etanercept, are emerging. Finally, it is important to acknowledge that topical and systemic treatments are only part of a 'total care' package combining treatment, disease-specific education, and psychological support to cope with a possible lifelong skin condition.

Citations

13 citations in Web of Science®
16 citations in Scopus®
Google Scholar™

Altmetrics

Additional indexing

Item Type:Journal Article, refereed, further contribution
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Dermatology Clinic
Dewey Decimal Classification:610 Medicine & health
Language:English
Date:2009
Deposited On:17 Mar 2010 14:03
Last Modified:07 Aug 2016 07:53
Publisher:Karger
ISSN:1421-5721
Publisher DOI:https://doi.org/10.1159/000232308
PubMed ID:19710554

Download

Full text not available from this repository.View at publisher

TrendTerms

TrendTerms displays relevant terms of the abstract of this publication and related documents on a map. The terms and their relations were extracted from ZORA using word statistics. Their timelines are taken from ZORA as well. The bubble size of a term is proportional to the number of documents where the term occurs. Red, orange, yellow and green colors are used for terms that occur in the current document; red indicates high interlinkedness of a term with other terms, orange, yellow and green decreasing interlinkedness. Blue is used for terms that have a relation with the terms in this document, but occur in other documents.
You can navigate and zoom the map. Mouse-hovering a term displays its timeline, clicking it yields the associated documents.

Author Collaborations